Aethlon Medical Announces Fiscal Year End

Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Australian oncology study advances into Cohort

3 as enrollment continues

the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained

a focus on managing operating expenses.

Conference Call Today at 4:30 p.m. ET

SAN DIEGO, June 10, 2026 -- Aethlon Medical, Inc.

(the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and

life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31,

2026, and provided an update on recent developments.

"Fiscal 2026 was a year of meaningful execution

for Aethlon as we advanced our Australian oncology study through the first two cohorts and recently initiated Cohort 3. Advancement

into the final cohort represents an important clinical milestone as we work toward generating data that may help define the optimal treatment

regimen and guide future development decisions. We also strengthened the Hemopurifier platform through expansion of our intellectual

property portfolio and advancement of preclinical research supporting potential applications beyond oncology. Combined

with our continued focus on managing operating expenses, these achievements position us to pursue multiple value-creating opportunities

across our clinical and research programs." said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon

Clinical Progress in Cancer Trial

Enrollment and treatment of participants in Cohort

2 of the Australian oncology trial have been completed. An independent Data Safety Monitoring Board reviewed the data, identified no safety

concerns based on its review of available data, and recommended advancing to the third and final cohort. Screening is actively underway

at the three investigative sites for this final cohort where 3-6 participants will be treated with 3 Hemopurifier sessions during a 1-week

period. The first participant in Cohort 3 of the study has been enrolled and received three Hemopurifier treatments without any device

deficiencies or immediate complications and is now in the follow-up period. Successful enrollment and treatment of the first participant

in Cohort 3 maintains the study's clinical momentum and moves the Company closer to completing enrollment and generating data from all

planned dosing regimens.

Serial Extracellular Vesicle and T cell measurements

on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the

effects of the three different Hemopurifier dosing regimens on these parameters will be performed by a CRO at the completion of the trial.

This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate

dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents,

Keytruda or Opdivo .

Other Recent Developments

During fiscal 2026, we strengthened our intellectual

property portfolio through the issuance of patents in both the United States and Europe covering 2 potential applications of the Hemopurifier

for coronavirus-related conditions; excessive clotting known as coagulopathy during acute COVID-19 infection and symptoms of Long COVID.

These patents extend protection for certain applications of the Hemopurifier into the 2040s.

In addition, we advanced our preclinical extracellular

vesicle (EV) research activities, including studies evaluating removal of EVs in plasma samples from patients with rheumatoid arthritis

and chronic kidney disease. These efforts support the Company's ongoing evaluation of the Hemopurifier's potential applications across

multiple disease categories and may create future opportunities to expand the platform into large markets

characterized by significant unmet medical need.

Separately, we continued our evaluation of Hemopurifier

compatibility with a simplified blood treatment system being developed by Stavro Medical. Initial testing assessing flow rates and transfer

of fluid through the Hemopurifier has been completed, and future studies evaluating removal of surrogate markers for extracellular vesicles

by the Hemopurifier using the system are under consideration. We believe this approach could expand potential treatment settings for the

Hemopurifier in the future and may improve the scalability and accessibility of treatment if successfully

developed and validated.

Subsequent to fiscal year-end, an interview published

in IEEE Spectrum featuring Aethlon's Chief Medical Officer and a physician involved in the treatment of an Ebola virus disease patient

with the Hemopurifier during the 2014 outbreak highlighted the Company's experience with Ebola treatment efforts. In connection with renewed

public health interest surrounding recent Ebola outbreaks, we also confirmed the continued availability of our FDA-authorized expanded

access (compassionate use) protocol and shared the protocol as well as past in vitro and in vivo data with organizations involved in global

and U.S. emerging pathogen preparedness efforts, including the World Health Organization's R&D Blueprint expert panel and the National

Emerging Special Pathogen Training and Education Center.

Financial Results for the Fiscal Year Ended

As of March 31, 2026, the Company had approximately

$5.0 million in cash and cash equivalents, providing resources to support ongoing clinical and research activities.

Subsequent to fiscal year-end, the Company strengthened

its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program.

Consolidated operating expenses declined 21.9%

year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company's

clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025. The decrease was primarily due to

$1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction

in professional fees.

Consistent with the reduction in operating expenses,

the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year.

Other income was approximately $142,000 for the

fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances, compared to other expense of approximately

$4 million in the prior fiscal year. The prior-year amount included approximately $4.7 million of non-cash financing-related charges.

Net loss attributable to our common stockholders

was $7.2 million for the fiscal year ended March 31, 2026, compared to net loss of $13.4 million for the fiscal year ended March 31, 2025.

The consolidated balance sheets for March 31,

2026, and March 31, 2025, and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025, are included

at the end of this release.

Management will host a conference call today,

Wednesday, June 10, 2026, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following

management's formal remarks, there will be a question-and-answer session.

Interested parties can register for the conference

call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note that registered

participants will receive their dial-in number upon registration.

Interested parties without internet access or

unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical,

Inc. conference call.

A replay of the call will be available approximately

one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical's website or by dialing

1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number

About the Hemopurifier

The Aethlon Hemopurifier is an investigational

medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally

with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich

surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies

and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Administration

Breakthrough Device Designation for:

The treatment of individuals with advanced or